CYP1B1 and breast carcinoma: Nevertheless, since biotransformation of tamoxifen, a widely used drug in breast cancer treatment, occurs via CYP1B1[32], the mis-expression of CYP1B1 in breast cancer cells due to miR-27b could influence the efficacy of tamoxifen.